Back to search
Platinum-Resistant Fallopian Tube Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Platinum-Resistant Fallopian Tube Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Platinum-Resistant Fallopian Tube Carcinoma trials you may qualify forTo evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants wi…
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resis…
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gyn…
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian c…
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participa…
The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.
This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination wi…
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovari…